

Avastin® (bevacizumab) – Expanded indication

- On June 13, 2018, [Genentech announced](#) the FDA approval of [Avastin \(bevacizumab\)](#), in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
 - Other approved uses for Avastin in ovarian, fallopian tube, and peritoneal cancer include: in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens; and in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Avastin is also indicated for the treatment of metastatic colorectal cancer; non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent, or metastatic cervical cancer.
- In 2018, more than 22,000 women will be diagnosed with ovarian cancer in the U.S. and approximately 14,000 will die from the disease.
 - About 80% of ovarian cancer cases are diagnosed at an advanced stage when the cancer has spread beyond the ovaries.
- The expanded indication for Avastin was based on a placebo-controlled trial in patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients were randomized to one of three arms: carboplatin plus paclitaxel (CP) followed by placebo alone, CP plus bevacizumab (CPB) followed by placebo alone, or CPB followed by bevacizumab monotherapy (CPBB). The primary endpoint was progression-free survival (PFS).
 - The median PFS was 12 months for the CP arm, 12.8 months for CPB, and 18.2 months for CPBB (HR = 0.62 relative to the CP arm [95% CI: 0.52, 0.75], $p < 0.0001$).
 - The secondary endpoint of overall survival was 40.6 months for the CP arm, 38.8 months for the CPB arm, and 43.8 months for the CPBB arm.
- Avastin carries a boxed warning for gastrointestinal perforations, surgery and wound healing complications, and hemorrhage.
- In patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection, the recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent, for a total of up to 22 cycles or until disease progression, whichever occurs earlier.

- Refer to the Avastin drug label for dosage information in other indications, including platinum-resistant and platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.